Technology | January 07, 2011

Alternative to Arteriotomies and Vascular Closure Implants Now Available in U.S.

January 7, 2011 – A new access device is now available in cath labs across the United States. The Arstasis One Access Device, from Arstasis, is the first commercially available alternative to the Seldinger Technique in 52 years. Previously, only a select number of physicians participating in Arstasis clinical trials and select pre-launch registries have been able to use the device. "We are delighted to begin providing U.S. cardiologists with a femoral artery access device that allows them to perform angiography without resorting to inserting a vascular closure implant into the patient," said Bruce Modesitt, CEO of Arstasis. Along with the U.S. launch, patient enrollment is continuing in the RECITAL study. The non-randomized, prospective, post-market registry is anticipated to enroll up to 500 patients in at least seven U.S. hospitals. Since 1959, physicians have been using the Modified Seldinger Technique to insert flexible catheters into the femoral artery for performing procedures in the patient's arterial-vascular system. It is estimated that the most prevalent such procedure, diagnostic angiography, is performed more than half a million times per month worldwide. At the end of every such case, patients are left with a substantial hole in their femoral artery, which typically takes significant effort and cath lab resources to close. With the Arstasis One Access Device, however, physicians create a shallow-angle needle pathway through the wall of the femoral artery. When the sheath is withdrawn, the shallow-angle pathway collapses from the normal pressure of the patient's femoral artery blood flow and approximately three to four minutes of mild, non-occlusive finger-pressure. This quickly seals the access site. For more information: www.arstasis.com

Related Content

Vascade MVP Reduces Time to Ambulation Follow EP Procedures
News | Vascular Closure Devices | November 11, 2018
The Vascade MVP vascular closure system met its endpoints compared to manual compression in a pivotal clinical study...
Technology | Vascular Closure Devices | November 05, 2018
November 2, 2018 — Cordis, a Cardinal Health company, today announced the U.S.
Teleflex Acquires Essential Medical
News | Vascular Closure Devices | October 05, 2018
Teleflex Inc. announced the acquisition of Essential Medical Inc. Based in Exton, Pa., Essential Medical is a privately...
Cardiva Medical Announces Completion of the AMBULATE Pivotal Trial
News | Vascular Closure Devices | May 10, 2018
Cardiva Medical Inc. announced the completion of the AMBULATE pivotal trial, one of several clinical trials in the...
Cardiva Medical Announces $41 Million for AMBULATE Vascular Closure Device Trial
News | Vascular Closure Devices | February 21, 2018
Vascular closure device provider Cardiva Medical announced that the company has closed on $11 million in additional...
The bioresorbable Cordis Mynx Grip vascular closure device seals arteriotomies without use of permanent hardware.

The bioresorbable Cordis MynxGrip vascular closure device seals arteriotomies without use of permanent hardware.

Feature | Vascular Closure Devices | January 22, 2018 | Dave Fornell
While manual compression remains the gold standard for hemostasis of catheterization vascular access site arteriotomi
Vivasure Enrolls First Patient in Frontier IV Clinical Trial
News | Vascular Closure Devices | December 29, 2017
Vivasure Medical announced in October the successful enrollment of the first patient in the Frontier IV clinical study...
Enrollment Completed in U.S. IDE Trial for Manta Large Bore Vascular Closure Device
News | Vascular Closure Devices | December 22, 2017
Essential Medical announced the completion of enrollment in the U.S. pivotal investigational device exemption (IDE)...
Overlay Init